Kardigan Reports Q2 2026 Financial Results and Pipeline Updates
Health
Earnings
IPO:
Jun 18, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Aug 11, 2026 7:18 AM ET
South San Francisco, CA, and Princeton, NJ, USA - Kardigan, Inc. (Nasdaq: KARD), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, reported financial results for the second quarter ended June 30, 2026, and provided recent business updates.
... Read on — Members only
About Kardigan, Inc.
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale.
Health
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.